Literature DB >> 21166734

Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study.

S Roman1, A Hot1, N Fabien1, J-F Cordier1, P Miossec1, J Ninet1, F Mion1.   

Abstract

Esophageal involvement occurs in about 80% of patients with systemic sclerosis, with a marked diminution of peristaltic pressures in the distal two-thirds of the esophagus. Our aims were to more fully characterize esophageal motility disorders in systemic sclerosis using high-resolution manometry (HRM) and to determine predictive factors of esophageal involvement. Fifty-one patients (46 females) with systemic sclerosis were included in this retrospective study. Esophageal motility was characterized with HRM. The demographic data, esophageal symptoms, presence of other organ involvement, and autoantibody profile (anti-Scl70 antibodies [Scl70], anticentromere antibodies [ACA]) were recorded for all patients. Esophageal body dysmotility was present in 33 patients (67.3%) and was associated with hypotensive esophagogastric junction in 27 patients (55.1%). The velocity of proximal contractions was higher in patients with esophageal body dysmotility compared to patients with normal peristalsis (median 10.8 cm/s vs. 5.5, P = 0.04). The amplitude of middle esophageal contraction but not of distal esophageal contraction was reduced in patients with hypoperistalsis. Diffuse esophageal skin involvement, presence of Scl70 and absence of ACA were associated with esophageal involvement. Esophageal symptoms encountered in 87.5% of patients were not predictive of esophageal dysmotility. This HRM series confirms the high prevalence of esophageal body dysmotility in systemic sclerosis. Diffuse skin involvement, positive Scl70 and negative ACA, but not esophageal symptoms, may predict esophageal body dysmotility.
© 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Keywords:  esophagus; high‐resolution manometry; systemic sclerosis

Mesh:

Substances:

Year:  2010        PMID: 21166734     DOI: 10.1111/j.1442-2050.2010.01150.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  17 in total

1.  Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis.

Authors:  Shiko Kuribayashi; Sei-Ichiro Motegi; Kenichiro Hara; Yasuyuki Shimoyama; Hiroko Hosaka; Akiko Sekiguchi; Kouichi Yamaguchi; Osamu Kawamura; Takeshi Hisada; Osamu Ishikawa; Motoyasu Kusano; Toshio Uraoka
Journal:  J Gastroenterol       Date:  2019-04-01       Impact factor: 7.527

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review.

Authors:  Wouter Schutyser; Ludovic Cruyt; Jean-Baptiste Vulsteke; Jan L Lenaerts; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2019-11-11       Impact factor: 2.980

4.  The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters.

Authors:  J N Kimmel; D A Carlson; M Hinchcliff; M A Carns; K A Aren; J Lee; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2016-02-27       Impact factor: 3.598

Review 5.  Role and safety of fundoplication in esophageal disease and dysmotility syndromes.

Authors:  Charles T Bakhos; Roman V Petrov; Henry P Parkman; Zubair Malik; Abbas E Abbas
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.

Authors:  Ana Zekovic; Nemanja Damjanov
Journal:  Rheumatol Int       Date:  2017-03-07       Impact factor: 2.631

7.  Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.

Authors:  George P Karamanolis; Stylianos Panopoulos; Anastasios Karlaftis; Konstantinos Denaxas; Dimitrios Kamberoglou; Petros P Sfikakis; Spiros D Ladas
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

Review 8.  Advances in the evaluation and management of esophageal disease of systemic sclerosis.

Authors:  Dustin A Carlson; Monique Hinchcliff; John E Pandolfino
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

9.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

10.  Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis.

Authors:  Dustin A Carlson; Michael D Crowell; Jessica N Kimmel; Amit Patel; C Prakash Gyawali; Monique Hinchcliff; W Leroy Griffing; John E Pandolfino; Marcelo F Vela
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.